Busulfan 60 mg /10mL

Busulfan 60 mg /10mL

Product Overview

Generic NameBusulfan 60 mg /10mL
Brand Name(s)Busulfex®, Busilvex®
CategoryAntineoplastic / Cancer
FormSterile IV injection / concentrate for solution for infusion
Strength60 mg / 10 mL (6mg/mL)
Therapeutic ClassAlkylating antineoplastic agent; alkyl sulfonate; bifunctional alkylating agent
ATC CodeL01AB01

Manufacturing & Regulatory

ManufacturerOtsuka, Celon, Fresenius-Kabi
GMP ComplianceWHO-GMP
DMF/CEPType II DMF / LOA
COFEPRIS010.000.6307.00
Free Sale CertificateYes, available as COPP/CPP

Logistics & Export

MOQ8 vials
Shelf Life24 months at 2–8°C
StorageRefrigerated 2°C–8°C; do not freeze
IncotermsEXW, HS/HSN 30049099
Lead Time7 - 10 Business Days

Documentation Available Upon Request

Certificate of Analysis (PDF)Supplied per batch upon request
SDS-Safety Data Sheet (PDF)Request a GHS-compliant SDS/MSDS
CTD Summary (PDF)Not publicly available as a full CTD.

Special Notes

Clave 010.000.6307.00. Public-sector wording: BUSULFÁN, solución inyectable; cada mL contiene busulfán 6.0 mg; envase con 8 frascos ámpula o vial de 60 mg/10 mL. Busulfán 60 mg/10 mL is an intravenous cytotoxic alkylating agent used primarily as part of myeloablative conditioning regimens before haematopoietic stem-cell transplantation, commonly in combination with cyclophosphamide or other conditioning agents. It requires specialist hospital administration, therapeutic monitoring where applicable, seizure prophylaxis according to institutional protocol, and close monitoring for profound myelosuppression, infection, hepatic veno-occlusive disease/sinusoidal obstruction syndrome, pulmonary toxicity, mucositis, infertility, and embryo-foetal toxicity